Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of ALLO-ASC-CD in Crohn's Disease
NCT02580617Phase 1Unknown
- Sponsor
- Anterogen Co., Ltd.
- Start
- Nov 2015
- Primary completion
- Dec 2023
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allo-asc in Crohn's disease, sponsored by Anterogen Co., Ltd. Primary endpoint: Safety (Clinically measured abnormality of laboratory tests and adverse events) at 4 weeks. Status: unknown.
02
Drugs
allo-asc
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02580617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02580617.